AngioDynamics (ANGO) Q2 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Tue, January 6, 2026 astatine 11:23 AM CST 29 min read

Image source: The Motley Fool.

Jan. 6, 2026, 8 a.m. ET

• President and Chief Executive Officer — James Clemmer

• Executive Vice President and Chief Financial Officer — Stephen Trowbridge

Need a punctuation from a Motley Fool analyst? Email [email protected]

This presumption should beryllium work successful conjunction with the property merchandise discussing the company's operating results and fiscal show during this morning's league call. Unless different noted, each metrics and maturation rates mentioned during today's telephone are connected a pro forma basis, which exclude the results of the Dialysis and BioSentry businesses that were divested successful June 2023, the PICC and Midline products that were divested successful February 2024 and the Radiofrequency and Syntrax enactment catheter products that we discontinued successful February 2024. Also, unless different noted, each comparisons volition beryllium the 2nd fiscal 4th of 2026 versus the 2nd fiscal 4th of 2025.

Now I'd similar to crook the telephone implicit to Jim Clemmer, AndioDynamics' President and Chief Executive Officer. Mr. Clemmer?

James Clemmer: Thank you, operator. Good morning, everyone, and convey you for joining america for AngioDynamics' Fiscal 2026 Second Quarter Earnings Call. Joining maine contiguous is Steve Trowbridge, AngioDynamics' Executive Vice President and Chief Financial Officer. We delivered beardown results successful the 2nd quarter. Revenue grew 8.8% with Med Tech up 13%, and we translated that apical enactment show into improved profitability. Adjusted EBITDA astir doubled year-over-year, and we generated affirmative currency flow. These results beryllium that we tin thrust some gross maturation and profitability simultaneously. Based connected our beardown performance, we are raising our afloat twelvemonth guidance for some gross and adjusted EBITDA, which Steve volition item aboriginal successful the call.

What's peculiarly encouraging is the breadth of our execution crossed our portfolio. Auryon delivered different 4th of double-digit year-over-year growth. Our Mechanical Thrombectomy platforms proceed to summation traction, some commercially and from a regulatory merchandise improvement standpoint. NanoKnife is good positioned to capitalize connected the prostate accidental with the CPT codification becoming effectual a fewer days ago, and our Med Device concern delivered coagulated results. Now fto maine locomotion you done each of our businesses. Auryon continues to execute exceptionally well. We delivered our 18th consecutive 4th of double-digit growth, and we proceed to instrumentality stock successful the atherectomy market. Our strategy to summation penetration successful hospitals is working, driving some higher volumes and amended economics.